(905) 271 2709 mail@focalpointresearch.net
Focal Point
  • Home
  • About
  • Team
  • Services
    • Cosmetic Consultants
    • Natural Health Products
    • Drugs
    • Medical Devices
    • Consumer Products
    • Technology
    • FDA Consulting
    • Health Canada Consultants
    • Regulatory Affairs
    • Pharmacovigilance Services
  • Innovation
  • Articles
  • Contact
Select Page
Cannabis in Cosmetics; Where Are We Now

Cannabis in Cosmetics; Where Are We Now

by Emily C | Apr 28, 2020 | Canadian Regulatory, Cosmetics, Innovation, Natural Health Products, OTC Drugs, Research/Science/Technology, U.S. Regulatory

A couple of years ago the world began legalizing recreational cannabis, bringing it into the cosmetic industry. Since then, it has been reported that the cosmetic CBD market has a net worth of 710 million US dollars and is projected to have a net worth of 959 million...
Health Canada Guidance Document on Interim Expedited Hand Sanitizer Approval Process

Health Canada Guidance Document on Interim Expedited Hand Sanitizer Approval Process

by Emily C | Apr 16, 2020 | Canadian Regulatory, Natural Health Products

Health Canada has released a guide document pertaining to the temporary expedited process for the production and distribution of hand sanitizers in Canada. The document highlights acceptable quality grades and medicinal ingredient concentrations, formulation...
A Summary of International Efforts in Minimizing the Spread of COVID-19

A Summary of International Efforts in Minimizing the Spread of COVID-19

by Emily C | Apr 3, 2020 | Canadian Regulatory, Innovation, Medical Devices, Research/Science/Technology, U.S. Regulatory

Recently, information has been provided regarding updates that Health Canada and the U.S. FDA have done in order to aid in the battle against COVID-19. However, other countries have also taken drastic measures to assist with reducing the spread of COVID-19. The...
Health Canada Extension on Nitrosamine Risk Assessments

Health Canada Extension on Nitrosamine Risk Assessments

by Emily C | Apr 3, 2020 | Canadian Regulatory, Medical Devices, Natural Health Products, Research/Science/Technology

Earlier this year, information about new regulations and requirements put in place by Health Canada for product’s containing nitrosamine impurities was released. These regulations are applicable to prescription and non-prescription pharmaceuticals containing...

Recent Posts

  • FDA OTC MONOGRAPH DRUG USER FEE RATES FOR FISCAL YEAR 2021
  • Phase I of the Self-Care Framework
  • Changes to INCI Names for Hydrocarbons
  • Health Canada Risk Evaluation of N-nitrosamine Impurities: First Step Deadline Fast Approaching
  • Interim Order No. 2 Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19 (IO No. 2)

Recent Comments

    Archives

    • March 2021
    • February 2021
    • January 2021
    • November 2020
    • October 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • April 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • November 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • May 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • May 2018
    • April 2018
    • March 2018
    • February 2018
    • January 2018

    Categories

    • Canadian Quality Assurance
    • Canadian Regulatory
    • Cosmetics
    • European Regulatory
    • Events/Company Updates
    • Importation of NHPs
    • Innovation
    • Innovation
    • Medical Devices
    • Natural Health Products
    • OTC Drugs
    • Our View
    • Research/Science/Technology
    • U.S. Regulatory
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Copyright © 2021 Focal Point Research Inc.
    Privacy Policy | Terms of Use
    Website Design and Development by PLAY